SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?


To: Icebrg who wrote (3744)12/18/2002 6:34:29 PM
From: scaram(o)uche  Respond to of 10345
 
>> GLGS has about 37 mio. shares outstanding and a market cap. of abt 12 mUSD to put the above figures in some perspective. <<

Looks like the conversion factor is probably 1K:1? From the last prospectus......

As of
December 31, 2001, Elan International Services, Ltd. has purchased $1.47
million of the Company's shares of Series B Convertible Preferred Stock
pursuant to such agreement, constituting 862.76047 shares.


From the last 10-K.......

As part of the transaction, Elan International also purchased 2,700,000 shares
of the Company's Common Stock, 1,116.79 shares of the Company's Series C
Non-Voting Preferred Stock ("Series C Stock") convertible into 1,116,790 shares
of Common Stock after two years and a five-year warrant to purchase 381,679
shares of Common Stock at an exercise price of $2.43 per share for an aggregate
purchase price of $5,000,000. Elan International also purchased shares of the
Company's Series A Convertible Exchangeable Non-Voting Preferred Stock ("Series
A Stock") for $12,015,000. The Series A Stock bears a 7% dividend
payable-in-kind. The Series A Stock is exchangeable at the option of Elan
International at any time for all of the preferred stock of SafeScience Newco,
Ltd. held by the Company which, if exchanged, would give Elan International 50%
ownership of the fully diluted equity in SafeScience Newco, Ltd. The Series A
Stock shall be redeemed by the Company, if still outstanding on July 10, 2007
for either cash, shares of Common Stock, or shares of Common Stock and a warrant
of the Company at their fair market value at the time of redemption, at its
option. The proceeds from the issuance of the Series A Stock were contributed by
the Company to SafeScience Newco, Ltd. Consequently, the value assigned to the
Company's investment in SafeScience Newco, Ltd. is the same as the value of the
Series A Stock issued, which was approximately $12,015,000.


edit..... more......

4. On July 10, 2001 Elan International Services, Ltd. ("EIS") purchased
2,700,000 shares of Common Stock, 1,116.79 shares of Series C

<PAGE>

Preferred Stock convertible into 1,116,790 shares of Common Stock after
two years, and a five-year warrant to purchase 381,679 shares of Common
Stock at an exercise price of $2.43 per share for an aggregate purchase
price of $5,000,000. EIS also purchased 4,944.44 shares of Series A
Preferred Stock for $12,015,000.


It's fairly apparent. The shares are worth little now. But if GG is successful, they'll be worth a bundle. Nothing new here, as such was the foundation of the Geaney Ponzi.



To: Icebrg who wrote (3744)12/18/2002 6:48:13 PM
From: Icebrg  Read Replies (1) | Respond to of 10345
 
Curis is continuing their re-focus campaign. Or shall we call it their survival efforts. A couple of years too late, perhaps. Soon there will only be hedgehogs left. Let's hope that Elan at least looks kindly at that j/v.

CAMBRIDGE, Mass., Dec. 18 /PRNewswire-FirstCall/ -- Curis, Inc. (Nasdaq: CRIS - News) announced today it has assigned and licensed Curis patent rights related to the development of cellular therapeutics for the treatment of diabetes to ES Cell International Pte Ltd (ESI), which develops stem cells as therapeutic products for various human disorders. As part of the overall transaction, ESI will assume all responsibility for future development and clinical testing of Curis' diabetes stem-cell technologies and cover FTE costs. This agreement is the latest in a series of transactions reinforcing Curis' efforts to streamline its in-house research and development, and license out non-core assets.



To: Icebrg who wrote (3744)1/8/2003 8:43:06 AM
From: Icebrg  Read Replies (1) | Respond to of 10345
 
Technology Behind GlycoGenesys' Oncology Drug Candidate Subject of Journal of National Cancer Institute Publication
Wednesday January 8, 8:32 am ET

Study Reports Patented Pectin Derived Compound Inhibits Cancer Tumor Growth and Metastasis In Mouse Models

BOSTON--(BUSINESS WIRE)--Jan. 8, 2003-- GlycoGenesys, Inc. (NASDAQ:GLGS - News) today announced that researchers from the Barbara Ann Karmanos Cancer Institute released a study in the current edition of the Journal of National Cancer Institute Volume 94, Issue 24 involving technology which the Barbara Ann Karmanos Cancer Institute and Wayne State University have exclusively licensed their worldwide rights to GlycoGenesys, Inc. The article by Drs. Raz, Nangia-Makker and colleagues, entitled "Inhibition of Human Cancer Cell Growth and Metastasis in Nude Mice by Oral Intake of Modified Citrus Pectin," describes a study comparing mice injected with human breast or colon cancer cells and fed modified citrus pectin to a control group that were not. The study found that both the breast and colon human cancer tumor growth, tumor blood vessel formation (angiogenesis), and metastasis were significantly inhibited in the mice receiving modified citrus pectin as compared to the control group.

The Company's human therapeutic candidate for the treatment of multiple indications of cancer GCS-100 is a formulation of modified citrus pectin being developed currently for IV administration. GCS-100 has been evaluated in Phase II(a) clinical trials for both colorectal and pancreatic cancer. In February 2002, the Company initiated a Phase I dose escalation trial of GCS-100 up to 80 mg/m2 at Sharp Clinical Oncology Research in San Diego, California.

GlycoGenesys, Inc.

GlycoGenesys is a biopharmaceutical company that develops and licenses products based on glycobiology. The Company's human therapeutic product GCS-100, a unique compound to treat cancer, has been evaluated in Phase II(a) human clinical trials for both colorectal and pancreatic cancers. In February 2002, the Company initiated a Phase I dose escalation trial of GCS-100 up to 80 mg/m2 at Sharp Clinical Oncology Research in San Diego, California. In the area of agriculture, GlycoGenesys continues to seek strategic alternatives for Elexa-4® Plant Defense Booster. Further information is available on GlycoGenesys' web site: www.glycogenesys.com.

The j/v is no more, although Elan has retained an interest in the company. Apart from that the take-home message seems to be: "Eat more lemons, or else".

Erik